Katharina Prieske1, Malik Alawi2, Leticia Oliveira-Ferrer3, Anna Jaeger3, Kathrin Eylmann3, Eike Burandt4, Barbara Schmalfeldt3, Simon A Joosse5, Linn Woelber3. 1. Department of Gynaecology and Gynaecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: k.prieske@uke.de. 2. Bioinformatics Core Facility, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Department of Gynaecology and Gynaecologic Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 4. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5. Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Abstract
BACKGROUND: Despite increasing incidence, vulvar squamous cell carcinoma (VSCC) is still a rare disease. Until now, two etiological pathways have been described: a high-risk human papillomavirus (HPV)-dependent route and an HPV-independent pathway often associated with lichen sclerosus. To date, therapeutic strategies in VSCC are not influenced by molecular pathological information and therapeutic options for advanced or recurrent disease are limited. METHODS: Whole exome sequencing of DNA, isolated from 34 VSCC samples and matched normal tissue for each individual was performed on an Illumina HiSeq4000. Short variant discovery was carried out using BWA mem and FreeBayes. Variants were annotated using ANNOVAR. RESULTS: FIGO stages were: IB (n = 7), II (n = 11), III (n = 8), and IVA (n = 3), (n = 5 unknown). TP53 missense mutations were most commonly detected with 56% (19/34). 12/34 (35.3%) samples were HPV positive (all HPV16), HPV positivity and TP53 mutations were mutually exclusive (p < .0001). Additionally, we observed mutations in known cancer relevant genes, like NBPF1 (n = 7), MACF1 (n = 5), SYNE2 (n = 5), DOCK2 (n = 4), KMT2D (n = 4), MAP2 (n = 4), NACA (n = 4), PIK3CA (n = 4), SYNE1 (n = 4), FBWX7 (n = 3), MSH6 (n = 3), NSD1 (n = 3), POLE (n = 3), TSC2, (n = 3) and CDKN2A (n = 2), but at considerably lower frequencies. For the total cohort 1848 cancer related mutations were detected (median of 54.4 per sample). CONCLUSIONS: The key mutation in HPV negative vulvar carcinoma affects TP53. While a multitude of cancer related mutations was detected in various samples, only few mutations recur and/or affect concurrent signaling pathways.
BACKGROUND: Despite increasing incidence, vulvar squamous cell carcinoma (VSCC) is still a rare disease. Until now, two etiological pathways have been described: a high-risk human papillomavirus (HPV)-dependent route and an HPV-independent pathway often associated with lichen sclerosus. To date, therapeutic strategies in VSCC are not influenced by molecular pathological information and therapeutic options for advanced or recurrent disease are limited. METHODS: Whole exome sequencing of DNA, isolated from 34 VSCC samples and matched normal tissue for each individual was performed on an Illumina HiSeq4000. Short variant discovery was carried out using BWA mem and FreeBayes. Variants were annotated using ANNOVAR. RESULTS: FIGO stages were: IB (n = 7), II (n = 11), III (n = 8), and IVA (n = 3), (n = 5 unknown). TP53 missense mutations were most commonly detected with 56% (19/34). 12/34 (35.3%) samples were HPV positive (all HPV16), HPV positivity and TP53 mutations were mutually exclusive (p < .0001). Additionally, we observed mutations in known cancer relevant genes, like NBPF1 (n = 7), MACF1 (n = 5), SYNE2 (n = 5), DOCK2 (n = 4), KMT2D (n = 4), MAP2 (n = 4), NACA (n = 4), PIK3CA (n = 4), SYNE1 (n = 4), FBWX7 (n = 3), MSH6 (n = 3), NSD1 (n = 3), POLE (n = 3), TSC2, (n = 3) and CDKN2A (n = 2), but at considerably lower frequencies. For the total cohort 1848 cancer related mutations were detected (median of 54.4 per sample). CONCLUSIONS: The key mutation in HPV negative vulvar carcinoma affects TP53. While a multitude of cancer related mutations was detected in various samples, only few mutations recur and/or affect concurrent signaling pathways.
Authors: Elysha Kolitz; Elena Lucas; Gregory A Hosler; Jiwoong Kim; Suntrea Hammer; Cheryl Lewis; Lin Xu; Andrew T Day; Melissa Mauskar; Jayanthi S Lea; Richard C Wang Journal: J Invest Dermatol Date: 2021-10-28 Impact factor: 7.590
Authors: Shatavisha Dasgupta; Patricia C Ewing-Graham; Thierry P P Van Den Bosch; Sigrid M A Swagemakers; Lindy A M Santegoets; Helena C Van Doorn; Peter J Van Der Spek; Senada Koljenović; Folkert J Van Kemenade Journal: Oncol Lett Date: 2021-03-16 Impact factor: 2.967
Authors: Jaroslav Nunvar; Lucie Pagacova; Zuzana Vojtechova; Nayara Trevisan Doimo de Azevedo; Jana Smahelova; Martina Salakova; Ruth Tachezy Journal: Biomolecules Date: 2021-05-20
Authors: Katharina Prieske; Malik Alawi; Anna Jaeger; Maximilian Christian Wankner; Kathrin Eylmann; Susanne Reuter; Patrick Lebok; Eike Burandt; Niclas C Blessin; Barbara Schmalfeldt; Leticia Oliveira-Ferrer; Simon A Joosse; Linn Woelber Journal: Cancers (Basel) Date: 2021-12-19 Impact factor: 6.639